Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, August 4, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrea Tan Maintained (ABCL) at Strong Buy with Decreased Target to $24 on, Aug 4th, 2023
Andrea Tan of Goldman Sachs, Maintained "AbCellera Biologics Inc." (ABCL) at Strong Buy with Decreased Target from $27 to $24 on, Aug 4th, 2023.
Andrea has made no other calls on ABCL in the last 4 months.
There is 1 other peer that has a rating on ABCL. Out of the 1 peers that are also analyzing ABCL, 0 agree with Andrea's Rating of Hold.
This is the rating of the analyst that currently disagrees with Andrea
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $28 on, Friday, May 5th, 2023
